Biosimilars

What are biosimilars? The Pharmacy Times® Biosimilars resource center keeps those in the space up to date with the latest clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.
 

What can we help you find?
[[thumbnail_alt_text]]
A discussion on limiting the number of biosimilars available for the same product at an institution regarding inventory, fridge space, and safety.
[[thumbnail_alt_text]]
The panel explores the appropriateness of switching from a biologic to a biosimilar through consideration of factors such as the curative vs noncurative setting, the EMR system, and patient education.
[[thumbnail_alt_text]]
The FDA does not usually require animalstudies for biosimilars; therefore, the process can move directly to pharmacokinetic and pharmacodynamic studies.
[[thumbnail_alt_text]]
Considerations for certain patient factors when recommending a biosimilar over a biologic to treat a patient.
[[thumbnail_alt_text]]
Marc Earl, PharmD, BCOP, and Tim Peterson, PharmD, BCOP, share their clinical experience with P&T committee decisions, the cost of switching, and the payor selection process for a patient.
[[thumbnail_alt_text]]
How biologics have changed clinical practice over conventional chemotherapies and currently available biosimilars in the US.
[[thumbnail_alt_text]]
Defining what it means to have an “interchangeability” designation as it relates to biosimilars and insight on challenges with regulations of holding this status.
[[thumbnail_alt_text]]
A review of the steps of the FDA approval process for biosimilars and a discussion on immunogenicity and quality assurance for biosimilars.
[[thumbnail_alt_text]]
Clinical pharmacists provide an overview of the similarities and differences of biosimilars vs biologics including a comparison of dosing and storage conditions.
[[thumbnail_alt_text]]
A session on the use of biosimilars, a topic that many pharmacists identify to be of growing importance in their practices, concluded the 2019 Directions in Oncology Pharmacy conference.
[[thumbnail_alt_text]]
Pfizer will become the first to launch 3 oncology monoclonal antibody biosimilar treatments to the US market.
[[thumbnail_alt_text]]
Biosimilars, which at the most simplistic level can be thought of as a type of generic option for a biologic, offer an opportunity to help reduce total biologic drug spend.